Cargando…

Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study

PURPOSE: Although chemotherapy is standard of care for metastatic colorectal cancer (mCRC), immunotherapy has no role in microsatellite stable (MSS) mCRC, a “cold” tumor. PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from 7 tumor-associated antigens (TAA) frequently expressed in mC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hubbard, Joleen M., Tőke, Enikő R., Moretto, Roberto, Graham, Rondell P., Youssoufian, Hagop, Lőrincz, Orsolya, Molnár, Levente, Csiszovszki, Zsolt, Mitchell, Jessica L., Wessling, Jaclynn, Tóth, József, Cremolini, Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Clinical Trials: Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365360/ https://www.ncbi.nlm.nih.gov/pubmed/35472243 http://dx.doi.org/10.1158/1078-0432.CCR-22-0112

Ejemplares similares

In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines
por: Lőrincz, Orsolya, et al.
Publicado: (2021)

T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters
por: Somogyi, Eszter, et al.
Publicado: (2023)

A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects
por: Somogyi, Eszter, et al.
Publicado: (2021)

The Poore’s Plague and Mr. Pepys
por: Owen, G. R.
Publicado: (1926)

Peeps with Pepys at Hygiene and Medicine
por: Broadhurst, Jean
Publicado: (1928)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

WINPEPI (PEPI-for-Windows): computer programs for epidemiologists
por: Abramson, Joseph H
Publicado: (2004)

PEpiD: A Prostate Epigenetic Database in Mammals
por: Shi, Jiejun, et al.
Publicado: (2013)

Which Molins treated Cromwell for stone--and did not prescribe for Pepys?
por: Morris, G C
Publicado: (1982)

Correction: PEpiD: A Prostate Epigenetic Database in Mammals
por: Shi, Jiejun, et al.
Publicado: (2013)

The Attitude of Great Writers Towards Disease: Pepys on the Great Plague
Publicado: (1893)

Samuel Pepys and His Diary: A Digression, Mainly Medical
por: Carter, H. S.
Publicado: (1948)

Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
por: Wu, Shaowei, et al.
Publicado: (2023)

Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study
por: Moretto, Roberto, et al.
Publicado: (2023)

A Short Account of Pepys’ Oculist, D’Urberville, and His Family
por: Pitfield, Robert L.
Publicado: (1928)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
por: Cui, ChuanLiang, et al.
Publicado: (2022)

Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
por: Miller, Katherine E., et al.
Publicado: (2022)

Proline iminopeptidase PepI overexpressing Lactobacillus casei as an adjunct starter in Edam cheese
por: Navidghasemizad, Sahar, et al.
Publicado: (2013)

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022)

CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
por: Li, Yibo, et al.
Publicado: (2023)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
por: Fu, Siqing, et al.
Publicado: (2022)

Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial
por: Monga, Varun, et al.
Publicado: (2021)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gm27pjbni7nl83ade50p4aimo4